Soft strain-insensitive bioelectronics featuring brittle materials.

Advancing electronics to interact with tissue necessitates meeting material constraints in electrochemical, electrical, and mechanical domains simultaneously. Clinical bioelectrodes with established electrochemical functionalities are rigid and mechanically mismatched with tissue. Whereas conductive materials with tissue-like softness and stretchability are demonstrated, when applied to electrochemically probe tissue, their performance is distorted by strain and corrosion. We devise a layered architectural composite design that couples strain-induced cracked films with a strain-isolated out-of-plane conductive pathway and in-plane nanowire networks to eliminate strain effects on device electrochemical performance. Accordingly, we developed a library of stretchable, highly conductive, and strain-insensitive bioelectrodes featuring clinically established brittle interfacial materials (iridium-oxide, gold, platinum, and carbon). We paired these bioelectrodes with different electrochemical probing methods (amperometry, voltammetry, and potentiometry) and demonstrated strain-insensitive sensing of multiple biomarkers and in vivo neuromodulation.

[Influence of MRD Status in Newly Diagnosed MM Patients with VGPR and Above after Treatment on Clinical Prognosis].

OBJECTIVE: To investigate the influence of MRD status in newly diagnosed MM patients with VGPR and above after treatment on clinical prognosis. METHODS: Clinical data of 210 newly diagnosed MM patients with VGPR and above after treatment in Fifth People's Hospital of Chendu city. from January 2010 to January 2018 were collected and retrospectively analyzed. The patients were divided into 2 groups: group A (152 patients with MRD-) and group B (58 patients with MRD+). The influencing factors of progression free survival and overall survival of patients were analyzed, and the correlation between MRD status and high-risk cytogenetic abnormalities, treatment plan and response to treatment were evaluated. RESULTS: There were no significant difference in clinical characteristics between the patients in 2 groups (P＞0.05). Single factor analysis showed that ASCT and MRD status were related with progression free survival of patients with newly diagnosed MM (P＜0.05). Multivariate analysis by Cox regression model showed that MRD+ persistence was the independent risk factor for progression free survival of patients with newly diagnosed MM (P＜0.05). The cumulative progression free survival rate in 2-year with follow-up of patients in group A was significantly higher than that in B group (P＜0.05). The median progression free survival time and overall survival time of patients with persistent MRD- were significantly longer than those of MRD+ (P＜0.05). The single factor analysis showed that MRD- maintenance time was the influencing factor of PFS and OS time of newly diagnosed MM patients (P＜0.05). The cumulative overall survival rate in 2-year with follow-up of patients with MRD- maintenance for 6 months was significantly higher than that of patients with MRD- maintenance for＜6 months (P＜0.05). The cumulative progression free survival rate and overall survival rate in 2 years with follow-up of patients with MRD- maintenance for ≥12 months were significantly higher than those of MRD-maintenance for ＜12 months（P＜0.05）. The median progression free survival time of patients with MRD- was significantly longer than that of patients with MRD+ who had≥ one kind of high-risk cytogenetic abnormality (P＜0.05). The MRD- rate of patients received ASCT was significantly higher than that of patients without ASCT (P＜0.05). The median progression free survival time of patients with MRD- was significantly longer than that of patients with MRD+ (P＜0.05). The maintenance time of MRD- in patients with bortezomib treatment was significantly longer than that of patients without bortezomib treatment in population with MRD- (P＜0.05). The median progression free survival time of patients with bortezomib treatment was significantly longer than patients without bortezomib treatment (P＜0.05). CONCLUSION: MRD+ maintenance in newly diagnosed MM patients with VGPR and above after treatment closely relates with poor long-term prognosis, however, the MRD- maintenance time can be used for prognosis evaluation. MRD+ suggests that patients possess the possibility of early recurrence, and dynamic monitoring of MRD status in treatment can be helpful to clinical determination of treatment opportunity for relapsed MM patients.

Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases.

Decitabine is a hypomethylating drug that is used to treat myelodysplastic syndrome (MDS) at a recommended dose and schedule (20 mg/m2 per day, for 5 consecutive days). However, due to its relatively high incidence of side effects and its effects on neoplastic cells, many studies have begun to explore the clinical application of a low dose of decitabine for treating MDS. In this retrospective study, we examined the effects of a very-low-dose decitabine schedule for treating MDS. A total of 13 patients diagnosed with de novo MDS received a schedule of intravenous decitabine administration at 6 mg/m2 per day for 7 days, repeated every 4 weeks. The complete response rate was 30.8%, and the overall response rate was 69.2%. In patients with complete remission, the median time to granulocyte recovery greater than 0.5 × 109/L during complete remission (CR) was 15 days. In patients with remission, the median time to granulocyte recovery greater than 0.5 × 109/L was 10.5 days. The 1-year survival rate was 72.7% and the median survival was 28.0 months. In summary, we demonstrated that a very-low-dose decitabine schedule has an appreciable response and survival rate, as well as appreciable tolerance and medical compliance for treating MDS.

Structural design and environmental applications of electrospun nanofibers.

Nanofibers have attracted extensive attention and been applied in various fields due to their high aspect ratio, high specific surface area, flexibility, structural abundance, etc. The electrospinning method is one of the most promising and effective ways to produce nanofibers. The electrospun nanofibers-based films and membranes have already been demonstrated to possess small pore sizes, larges specific surface area, and can be grafted with different functionalities to adapt to various purposes. The environmental applications of nanofibers are one of the essential application fields, and great achievements have been made in this field. To well summarize the development of nanofibers and their environmental applications, we review the nanofiber fabrication methods, advanced fiber structures, and their applications in the field of air filtration, heavy metal removal, and self-cleaning surface. We hope this review and summary can provide readers a comprehensive understanding of the structural design and environmental applications of electrospun nanofibers.

Rapid degradation of 2,4-dichloronitrobenzene in single-chamber microbial electrolysis cell with pre-acclimated bioanode: A comprehensive assessment.

2,4-dichloronitrobenzene (DClNB) as a typical refractory pollutant, exists in multifarious industrial wastewater widely and poses a serious threat to the environment. An ion exchange membrane (IEM)-free microbial electrolysis cell (MEC) with pre-acclimated bioanode was built and evaluated systematically for treatment of DClNB containing wastewater. Results showed that compared with the non-acclimated or IEM-equipped MECs, the pre-acclimated IEM-free MECs had the best DClNB removal efficiency of 91.3% under COD and DClNB loading rates of nearly 1000 kg m-3 d-1 and 100 g m-3 d-1. Both of anode pre-acclimation and IEM removal reduced the electron transfer resistance by 71.1 and 194.5 Ω, respectively. Compared to the pre-acclimated IEM-equipped MEC, the cathode current efficiency of pre-acclimated IEM-free MEC increased by 13.7%. Analysis of live/dead cell staining indicated that a higher proportion of live cells was observed in the acclimated anode biofilm (66.1% vs. 47.3%), and the detoxification of DClNB in the pre-acclimated IEM-free MECs was significantly better (p < 0.05) than those of non-acclimated or IEM-equipped MECs. This study contributes to the performance improvement of the MEC process for treatment of toxic industrial wastewater.

Tanshinone IIA inhibits acute promyelocytic leukemia cell proliferation and induces their apoptosis in vivo.

Tanshinone IIA (TanIIA) is a traditional Chinese agent and has been widely used for treatment of cardiovascular diseases. Our previous study has shown that TanIIA can induce the differentiation of acute promyelocytic leukemia (APL) cells by increasing C/EBPß expression and induce APL cell apoptosis in vitro. In this study, we evaluated the activity of TanIIA against APL in vivo. We found that treatment with TanIIA prevented APL-mediated reduction in body weights. Treatment with TanIIA inhibited the proliferation of APL cells and triggered APL cell apoptosis and differentiation in vivo. Treatment with TanIIA significantly prolonged the survival of APL-bearing mice. Our data indicate that TanIIA has potent anti-APL activity with little adverse effect.

[Therapeutic Efficacy of Qingre Jiedu and Huoxue Huayu Recipe in Prednisone-dependant Patients with Chronic Primary Immune Thrombocytopenic Purpura.]

OBJECTIVES: To observe the clinical efficacy of Qingre Jiedu and Huoxue Huayu Recipe on the prednisone-dependant patients with chronic primary immune thrombocytopenic purpura (CPITP). METHODS: Fifty prednisone-dependant CPITP patients were treated with Qingre Jiedu and Huoxue Huayu Recipe orally one dose a day,the dosage of prednisone for these patients was tapered according to the monitoring result of blood platelet count (BPC).The therapeutic efficacy in these patients was evaluated before and after Chinese medicine treatment over 4 weeks. RESULTS: After the treatment of chinese medicine,BPC was increased from (28.6±22.5) ×109 L-1 to (81.8±56.5)×109 L-1 (P<0.05).The dosage of prednisone was decreased from (28.1±15.2) mg/d to (8.0±9.4) mg/d (P<0.05).Complement response,response and no response rate were 2%,10% and 88% before Chinese medicine treatment,which were 30%, 46% and 24% after Chinese medicine treatment,respectively (P<0.05). CONCLUSIONS: Qingre Jiedu and Huoxue Huayu Recipe could be effective in the treatment of prednisone-dependant patients with CPITP,and could decrease the dosage of prednisone.

Tanshinone IIA in acute promyelocytic leukemia.

INTRODUCTION: The prognosis of acute promyelocytic leukemia (APL) has been significantly improved by the use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, the utility of these drugs is limited by resistance to ATRA and the side effects of ATO. It has been reported that Tanshinone IIA (Tan IIA), a diterpene quinone isolated from Salvia Miltiorrhiza Bunge, induces apoptosis in the APL cell line, NB4. The effect of Tan IIA on the ATRA-resistant APL cell line (MR2) is unknown. METHODS: In this study, the effects of Tan IIA and ATO, alone and in combination, on MR2 cell apoptosis were investigated using transmission electron microscopy, flow cytometry and Western blot analyses. RESULTS: Nuclear changes typical of apoptosis were observed in Tan IIA-treated MR2 cells. Apoptosis was shown to be induced in a dose- and time-dependent manner with the activation of caspase-3 resulting in upregulation of tumor necrosis factor-a expression, activation of caspase-8 and alteration in mitochondrial transmembrane potential with release of cytochrome c (cyto-c). Tan IIA and ATO acted synergistically on the induction of MR2 cell apoptosis. CONCLUSIONS: These data indicate that Tan IIA may be beneficial in the treatment of ATRA-resistant APL and in combination with ATO for APL therapy in the clinic.

C/EBPß and CHOP participate in tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro.

Our studies indicated that Tanshinone IIA (TanIIA), which is widely applied in the treatment of cardiovascular diseases with a rare occurrence of side effects, could promote APL cell differentiation and apoptosis. We found TanIIA induced the differentiation of NB4 and MR2 cells with elevated C/EBPß and CHOP. When C/EBPß was overexpressed in NB4 cells, the level of CD11b in the transfected cells was significantly elevated. When we used CHOP siRNA to suppress CHOP expression in NB4 cells and then treated these cells with a high concentration of TanIIA, the differentiation and apoptosis of these cells were both significantly increased. These data demonstrate that C/EBPß is critical for APL cell differentiation and apoptosis induced by TanIIA, and that CHOP acts as a negative regulator of C/EBPß activity. Our study suggested that TanIIA is a promising drug for treating newly diagnosed and ATRA-resistant APL, and a high concentration of TanIIA associated with inhibition of CHOP, maybe a potentially promising therapy strategy.